bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Below is a table of amino acids produced and identified in the "classic" 1952 experiment, as analyzed by Miller in 1952 and more recently by Bada and collaborators with modern mass spectrometry, the 2008 re-analysis of vials from the volcanic spark discharge experiment, and the 2010 re-analysis of vials from the H2S-rich spark discharge experiment. While not all proteinogenic amino acids have been produced in spark discharge experiments, it is generally accepted that early life used a simpler set of prebiotically-available amino acids.
Grave fields are one of the chief sources of information on prehistoric cultures, and numerous archaeological cultures are labelled and defined by their burial customs, such as the Urnfield culture of the European Bronze Age.
Yessotoxins are a group of lipophilic, sulfur bearing polyether toxins that are related to ciguatoxins. They are produced by a variety of dinoflagellates, most notably Lingulodinium polyedrum and Gonyaulax spinifera. When the environmental conditions encourage the growth of YTX producing dinoflagellates, the toxin(s) bioaccumulate in edible tissues of bivalve molluscs, including mussels, scallops, and clams, thus allowing entry of YTX into the food chain.
=== Writing === During an interview at the Deadline Hollywood, Kripke teased that the season would be exploring Vought's past to explore the myths surrounding the company and the United States in general, as the comics also explored flashbacks focused during World War II and the Vietnam War and wanted to explore over how the superhero phenomenon did not only altered the present but also parts from the past as well, while also exploring over how the politics can turn neighbors against each other and what actually means to be in America. He revealed that this was one of the reasons of introducing Soldier Boy in the season, since the history of Vought and the US was explored through the character given that he was the first superhero ever and has been around since the Second World War. Kripke revealed that the toxic masculinity would be the real-life issue of the season and would also show how it would be affecting the main characters after many of them are pushed to the limit. He detailed over how the toxic masculinity was an ongoing issue that as by today continues affecting the lives of a lot of men, with many of them being targeted for not being considered ‘manly’ enough and over how this becomes very destructive to the society and organizations. This was the main reason of Soldier Boy being introduced as he represents the embodiment of the toxic masculinity which is an issue that the world still faces thanks to the older generations.
Sources: en.wikipedia.org
=== Characters and setting === Decay is set in the same location and timeframe as Half-Life. Half-Life takes place at a laboratory called the Black Mesa Research Facility, situated in a remote desert in New Mexico. In Half-Life, the player takes on the role of Gordon Freeman, a scientist involved in an accident that opens an inter-dimensional portal to the borderworld of Xen, allowing the alien creatures of Xen to attack the facility. The player guides Freeman in an attempt to escape the facility and close the portal, ultimately traveling to Xen to do so. Like the previous expansions, Decay shows the story of Half-Life from the perspective of a different set of protagonists. In Decay, players assume the roles of Colette Green and Gina Cross, two doctors who work in the same labs as Freeman, analyzing anomalous materials and specimens retrieved from Xen in prior teleportation experiments. After the experiment that causes the alien invasion takes place, Green and Cross must work with two ranking members of the science team, Dr. Richard Keller and Dr. Rosenberg, to contain and stabilize the deteriorating situation in Black Mesa.
==== Testosterone ==== Testosterone is secreted by the testicles of males and the ovaries of females, although small amounts are also secreted by the adrenal glands. It is the principal male sex hormone and an anabolic steroid. See Testosterone: Aggression and criminality and Testosterone: Brain for more information on how testosterone effects behavior.
The President told Molotov that he visualized the enforced disarmament of our enemies and, indeed, some of our friends after the war; that he thought that the United States, England, Russia and perhaps China should police the world and enforce disarmament by inspection. The President said that he visualized Germany, Italy, Japan, France, Czechoslovakia, Rumania and other nations would not be permitted to have military forces. He stated that other nations might join the first four mentioned after experience proved they could be trusted. Roosevelt and Molotov continued their discussion of the Four Policemen in a second meeting on June 1. Molotov informed the President that Stalin was willing to support Roosevelt's plans for maintaining postwar peace through the Four Policemen and enforced disarmament. Roosevelt also raised the issue of postwar decolonization. He suggested that former colonies should undergo a period of transition under the governance of an international trusteeship prior to their independence. China was brought in as a member of the Big Four and a future member of the Four Policemen. Roosevelt was in favor of recognizing China as a great power because he was certain that the Chinese would side with the Americans against the Soviets. He said to British Foreign Secretary Anthony Eden, "In any serious conflict of policy with Russia, [China] would undoubtedly line up on our side." As it was before the Chinese Civil War was won by the Communists, he did not mean the Communist China, but the Republic of China.
=== Brain growth === Neuroanatomical studies and the association between autism and teratogens strongly suggest that autism affects brain development soon after conception. This anomaly appears to start a cascade of pathological events in the brain that are significantly influenced by environmental factors. Just after birth, the brains of children with autism tend to grow faster than usual, followed by normal or relatively slower growth in childhood. It is unknown whether early brain overgrowth occurs in all children with autism. It appears to be most prominent in the frontal and temporal lobes, which are associated with higher cognitive specializations such as social cognition, and language development. Hypotheses for the cellular and molecular bases of pathological early overgrowth include an excess of neurons that causes local overconnectivity in key brain regions, and disturbed neuronal migration during early gestation.
=== Table of standard amino acid alpha-helical propensities === Estimated differences in free energy change, Δ(ΔG), estimated in kcal/mol per residue in an α-helical configuration, relative to alanine arbitrarily set as zero. Higher numbers (more positive free energy changes) are less favoured. Significant deviations from these average numbers are possible, depending on the identities of the neighbouring residues.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.